Phase I trial of rituximab, cladribine, and temsirolimus (RCT) for initial therapy of mantle cell lymphoma

Combination of Rituximab, Bendamustine, and Cytarabine for Patients With Mantle-Cell Non-Hodgkin Lymphoma Ineligible for Intensive Regimens or Autologous Transplantation

(2013) Carlo Visco et al.   JOURNAL OF CLINICAL ONCOLOGY

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial

(2013) Mathias J Rummel et al.   LANCET

Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma

(2013) Michael L. Wang et al.   NEW ENGLAND JOURNAL OF MEDICINE

CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d'Etude des Lymphomes de l'Adulte

(2012) R. Delarue et al.   BLOOD

An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma

(2011) T. E. Witzig et al.   ANNALS OF ONCOLOGY

Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study

(2011) Stephen M Ansell et al.   LANCET ONCOLOGY

Cladribine plus rituximab is an effective therapy for newly diagnosed mantle cell lymphoma

(2011) Stephen E. Spurgeon et al.   LEUKEMIA & LYMPHOMA

Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma

(2009) Thomas M. Habermann et al.   BRITISH JOURNAL OF HAEMATOLOGY

Immunochemotherapy and Autologous Stem-Cell Transplantation for Untreated Patients With Mantle-Cell Lymphoma: CALGB 59909

(2009) Lloyd E. Damon et al.   JOURNAL OF CLINICAL ONCOLOGY

Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group

(2008) C. H. Geisler et al.   BLOOD

Long-term progression-free survival after early autologous transplantation for mantle-cell lymphoma

(2008) S Murali et al.   BONE MARROW TRANSPLANTATION

Long‐term results of the treatment of patients with mantle cell lymphoma with cladribine (2‐CDA) alone (95‐80‐53) or 2‐CDA and rituximab (N0189) in the North Central Cancer Treatment Group

(2008) David J. Inwards et al.   CANCER

Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma

(2008) Stephen M. Ansell et al.   CANCER

Effect of remission status and induction chemotherapy regimen on outcome of autologous stem cell transplantation for mantle cell lymphoma

(2008) Brian G. Till et al.   LEUKEMIA & LYMPHOMA